Medtronic plc. (MDT) Shares Bought by Noesis Capital Mangement Corp

Noesis Capital Mangement Corp grew its stake in Medtronic plc. (NYSE:MDT) by 2.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,400 shares of the medical technology company’s stock after purchasing an additional 2,495 shares during the period. Medtronic makes up about 3.3% of Noesis Capital Mangement Corp’s holdings, making the stock its 9th largest holding. Noesis Capital Mangement Corp’s holdings in Medtronic were worth $8,819,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of MDT. Parkside Financial Bank & Trust grew its position in shares of Medtronic by 22.4% in the second quarter. Parkside Financial Bank & Trust now owns 1,146 shares of the medical technology company’s stock valued at $102,000 after purchasing an additional 210 shares in the last quarter. BDO Wealth Advisors LLC purchased a new stake in shares of Medtronic in the second quarter valued at approximately $103,000. Motco grew its position in shares of Medtronic by 8.7% in the second quarter. Motco now owns 1,239 shares of the medical technology company’s stock valued at $110,000 after purchasing an additional 99 shares in the last quarter. Quadrant Capital Group LLC grew its position in shares of Medtronic by 21.5% in the second quarter. Quadrant Capital Group LLC now owns 1,639 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 290 shares in the last quarter. Finally, Birch Hill Investment Advisors LLC purchased a new stake in shares of Medtronic in the first quarter valued at approximately $120,000. Institutional investors and hedge funds own 81.74% of the company’s stock.

Medtronic plc. (MDT) opened at $81.48 on Friday. Medtronic plc. has a twelve month low of $69.35 and a twelve month high of $89.72. The company has a market capitalization of $110,147.66, a P/E ratio of 17.54, a P/E/G ratio of 2.25 and a beta of 1.00. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.40 and a quick ratio of 2.05.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.08. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The company had revenue of $7.05 billion for the quarter, compared to analysts’ expectations of $7.05 billion. During the same period in the prior year, the firm earned $1.12 earnings per share. The firm’s revenue was down 4.0% compared to the same quarter last year. equities analysts anticipate that Medtronic plc. will post 4.77 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, January 19th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.46 per share. This represents a $1.84 dividend on an annualized basis and a yield of 2.26%. The ex-dividend date of this dividend is Thursday, December 28th. Medtronic’s dividend payout ratio (DPR) is 50.41%.

In other Medtronic news, EVP Bryan C. Hanson sold 16,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $82.82, for a total transaction of $1,325,120.00. Following the transaction, the executive vice president now directly owns 88,818 shares in the company, valued at $7,355,906.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 48,000 shares of company stock worth $3,837,920 over the last 90 days. 0.31% of the stock is owned by insiders.

A number of equities research analysts have recently issued reports on MDT shares. BidaskClub lowered Medtronic from a “hold” rating to a “sell” rating in a research report on Saturday, August 26th. Royal Bank of Canada dropped their price target on Medtronic from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, October 9th. Zacks Investment Research upgraded Medtronic from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. SunTrust Banks set a $92.00 price target on Medtronic and gave the company a “buy” rating in a research report on Sunday, November 19th. Finally, Jefferies Group restated a “buy” rating and issued a $99.00 price target on shares of Medtronic in a research report on Thursday, November 23rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and fourteen have assigned a buy rating to the stock. Medtronic currently has an average rating of “Hold” and a consensus target price of $88.57.

WARNING: “Medtronic plc. (MDT) Shares Bought by Noesis Capital Mangement Corp” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/22/medtronic-plc-mdt-shares-bought-by-noesis-capital-mangement-corp.html.

About Medtronic

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit